{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:50:37Z","timestamp":1790787037164,"version":"4.1.0"},"reference-count":85,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>(1) Background: Genitourinary syndrome of menopause (GSM) is a medical condition that can affect breast cancer survivors (BCS). This is a complication that often can occur as a result of breast cancer treatment, causing symptoms such as vaginal dryness, itching, burning, dyspareunia, dysuria, pain, discomfort, and impairment of sexual function. BCS who experience these symptoms negatively impact multiple aspects of their quality of life to the point that some of them fail to complete adjuvant hormonal treatment; (2) Methods: In this systematic review of the literature, we have analyzed possible pharmacological and non-pharmacological treatments for GSM in BCS. We reviewed systemic hormone therapy, local hormone treatment with estrogens and androgens, the use of vaginal moisturizers and lubricants, ospemifene, and physical therapies such as radiofrequency, electroporation, and vaginal laser; (3) Results: The data available to date demonstrate that the aforementioned treatments are effective for the therapy of GSM and, in particular, vulvovaginal atrophy in BCS. Where possible, combination therapy often appears more useful than using a single line of treatment; (4) Conclusions: We analyzed the efficacy and safety data of each of these options for the treatment of GSM in BCS, emphasizing how often larger clinical trials with longer follow-ups are needed.<\/jats:p>","DOI":"10.3390\/ph16040550","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:29:58Z","timestamp":1680748198000},"page":"550","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4281-8308","authenticated-orcid":false,"given":"Lucia","family":"Merlino","sequence":"first","affiliation":[{"name":"Department of Maternal, Infantile and Urological Sciences, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-5430","authenticated-orcid":false,"given":"Giulia","family":"D\u2019Ovidio","sequence":"additional","affiliation":[{"name":"Department of Maternal, Infantile and Urological Sciences, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0568-3822","authenticated-orcid":false,"given":"Viviana","family":"Matys","sequence":"additional","affiliation":[{"name":"Department of Maternal, Infantile and Urological Sciences, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Piccioni","sequence":"additional","affiliation":[{"name":"Department of Maternal, Infantile and Urological Sciences, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5556-3933","authenticated-orcid":false,"given":"Maria Grazia","family":"Porpora","sequence":"additional","affiliation":[{"name":"Department of Maternal, Infantile and Urological Sciences, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Senatori","sequence":"additional","affiliation":[{"name":"Italian Society of Colposcopy and Cervicovaginal Pathology (SICPCV), 00186 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0979-8832","authenticated-orcid":false,"given":"Maria Federica","family":"Viscardi","sequence":"additional","affiliation":[{"name":"Department of Maternal, Infantile and Urological Sciences, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-8006","authenticated-orcid":false,"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Cattolica del Sacro Cuore University, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Della Rocca","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Policlinico Umberto I Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","first-page":"1","article-title":"A review of prognostic and predictive biomarkers in breast cancer","volume":"23","author":"Tarighati","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_3","unstructured":"(2023, February 24). Survivor. Dictionary of Cancer Terms. National Cancer Institute, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/survivor."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bpobgyn.2022.01.013","article-title":"Gynecological management of the breast cancer survivor","volume":"82","author":"Abel","year":"2022","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4\/6 Inhibitors: A Systematic Review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Capasso, I., Santoro, A., Cordisco, E.L., Perrone, E., Tronconi, F., Catena, U., Zannoni, G.F., Scambia, G., Fanfani, F., and Lorusso, D. (2023). Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer. Cancers, 15.","DOI":"10.3390\/cancers15051400"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13697130500487224","article-title":"Menopausal symptoms in women treated for breast cancer: The prevalence and severity of symptoms and their perceived effects on quality of life","volume":"9","author":"Gupta","year":"2006","journal-title":"Climacteric"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"The NAMS 2020 GSM Position Statement Editorial Panel (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 27, 976\u2013992.","DOI":"10.1097\/GME.0000000000001609"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GRF.0000000000000380","article-title":"Genitourinary Syndrome of Menopause","volume":"61","author":"Shifren","year":"2018","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17512433.2016.1215243","article-title":"Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients","volume":"9","author":"Poggio","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s42000-022-00427-1","article-title":"Hormone replacement therapy in BRCA mutation carriers: How shall we do no harm?","volume":"22","author":"Loizzi","year":"2023","journal-title":"Hormones"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s12282-021-01260-x","article-title":"Genitourinary symptoms in women with breast cancer: What do oncology health professionals think and do about them?","volume":"28","author":"Pearson","year":"2021","journal-title":"Breast Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clbc.2017.05.008","article-title":"Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists","volume":"17","author":"Biglia","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JOP.19.00297","article-title":"Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Common Complication with Effective Treatment Strategies","volume":"15","author":"Krishnamurthy","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_17","unstructured":"(2023, February 24). Available online: http:\/\/www.prisma-statement.org\/?AspxAutoDetectCookieSupport=1."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"North American Menopause Society (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 25, 1362\u20131387.","DOI":"10.1097\/GME.0000000000001241"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13697137.2020.1820478","article-title":"Vaginal lubricants and moisturizers: A review into use, efficacy, and safety","volume":"24","author":"Potter","year":"2020","journal-title":"Climacteric"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nappi, R.E., Martella, S., Albani, F., Cassani, C., Martini, E., and Landoni, F. (2022). Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?. Healthcare, 10.","DOI":"10.3390\/healthcare10081528"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"167283","DOI":"10.1155\/2015\/167283","article-title":"Regulation of Hyaluronan Synthesis in Vascular Diseases and Diabetes","volume":"2015","author":"Moretto","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejogrb.2018.08.008","article-title":"Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials","volume":"229","author":"Pitsouni","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1600-0781.2007.00320.x","article-title":"Polydeoxyribonucleotide promotes cyclobutane pyrimidine dimer repair in UVB-exposed dermal fibroblasts","volume":"23","author":"Belletti","year":"2007","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_24","first-page":"53","article-title":"A natural alternative to menopausal hormone replacement therapy. Phytoestrogens","volume":"54","author":"Arena","year":"2002","journal-title":"Minerva Ginecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40618-017-0801-0","article-title":"Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: A randomized double-blind placebo-controlled pilot study","volume":"41","author":"Bernorio","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00520-019-04684-6","article-title":"The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer","volume":"27","author":"Keshavarzi","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/gerona\/glab120","article-title":"Association of Vaginal Microbiota with Signs and Symptoms of the Genitourinary Syndrome of Menopause Across Reproductive Stages","volume":"76","author":"Shardell","year":"2021","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/GCO.0000000000000820","article-title":"Platelet rich plasma for the management of urogynecological disorders: The current evidence","volume":"34","author":"Prodromidou","year":"2022","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.sxmr.2019.11.005","article-title":"Vaginal Dilators: Issues and Answers","volume":"9","author":"Liu","year":"2020","journal-title":"Sex. Med. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/13697137.2015.1124259","article-title":"Treating vulvovaginal atrophy\/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition?","volume":"19","author":"Edwards","year":"2016","journal-title":"Climacteric"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/IJWH.S158913","article-title":"Current treatment options for postmenopausal vaginal atrophy","volume":"10","author":"Naumova","year":"2018","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00042192-200205000-00006","article-title":"Treatment of urogenital atrophy with low-dose estradiol: Preliminary results","volume":"9","author":"Santen","year":"2002","journal-title":"Menopause"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13697137.2013.807606","article-title":"Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy","volume":"16","author":"Simon","year":"2013","journal-title":"Climacteric"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS Recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/CAD.0b013e328365288e","article-title":"Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment","volume":"24","author":"Cavaliere","year":"2013","journal-title":"Anti-Cancer Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: The St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0039-6109(05)70443-6","article-title":"Breast cancer in men","volume":"76","author":"Donegan","year":"1996","journal-title":"Surg. Clin. N. Am."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1067\/mjd.2001.117432","article-title":"Estrogen production and action","volume":"45","author":"Nelson","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer","volume":"379","author":"Francis","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.18.00440","article-title":"Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women with Hormone Receptor\u2013Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial","volume":"37","author":"Ruhstaller","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1529-8019.2010.01354.x","article-title":"Atrophic vaginitis","volume":"23","author":"Stika","year":"2010","journal-title":"Dermatol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1188\/09.ONF.693-698","article-title":"Urogenital atrophy in breast cancer survivors","volume":"36","author":"Lester","year":"2009","journal-title":"Oncol. Nurs. Forum."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J. Oncol. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1524-4741.2011.01089.x","article-title":"Current overview of the management of urogenital atrophy in women with breast cancer","volume":"17","author":"Pruthi","year":"2011","journal-title":"Breast J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer\u2014Is it safe?), a randomised comparison: Trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Stockholm Breast Cancer Study Group: Menopausal hormone therapy after breast cancer: The Stockholm randomized trial","volume":"97","author":"Rutqvist","year":"2005","journal-title":"J. Natl. Cancer. Inst."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climacteric"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: A nested case\u2013control study","volume":"135","author":"Bonnetain","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"djac112","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: A Danish observational cohort study","volume":"114","author":"Cold","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/13697137.2018.1527306","article-title":"What should guide our patient management of vulvovaginal atrophy?","volume":"22","author":"Shapiro","year":"2019","journal-title":"Climacteric"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/AOG.0000000000001351","article-title":"ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer","volume":"127","author":"Farrell","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (2019). Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet, 394, 1159\u20131168.","DOI":"10.1016\/S0140-6736(19)31709-X"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JOP.18.00710","article-title":"Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy","volume":"15","author":"Sussman","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/GME.0000000000001463","article-title":"Systemic estradiol levels with low-dose vaginal estrogens","volume":"27","author":"Santen","year":"2019","journal-title":"Menopause"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2010.483297","article-title":"Minimized estradiol absorption with ultra-low-dose 10 microg 17b-estradiol vaginal tablets","volume":"13","author":"Waitzinger","year":"2010","journal-title":"Climacteric"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/GME.0000000000001138","article-title":"The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women\u2019s Sexual Health (ISSWSH) expert consensus panel review","volume":"25","author":"Simon","year":"2018","journal-title":"Menopause"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/GME.0000000000000672","article-title":"Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and\/or hormonal therapy for breast cancer: A retrospective study","volume":"23","author":"Pagano","year":"2016","journal-title":"Menopause"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/GME.0000000000000910","article-title":"Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause","volume":"24","author":"Labrie","year":"2017","journal-title":"Menopause"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00520-017-3960-9","article-title":"Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: A phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: A randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2017-01138","article-title":"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors","volume":"102","author":"Santen","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-019-05384-9","article-title":"Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study","volume":"178","author":"Pearson","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_68","first-page":"1576359","article-title":"Laser Therapy in the Treatment of Female Urinary Incontinence and Genitourinary Syndrome of Menopause: An Update","volume":"2019","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3109\/13697137.2015.1045485","article-title":"Vaginal erbium laser: The second-generation thermotherapy for the genitourinary syndrome of menopause","volume":"18","author":"Gambacciani","year":"2015","journal-title":"Climacteric"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jsxm.2021.12.010","article-title":"CO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis","volume":"19","author":"Filippini","year":"2022","journal-title":"J. Sex. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5306\/wjco.v13.i2.71","article-title":"Management of genitourinary syndrome of menopause in breast cancer survivors: An update","volume":"13","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10103-018-2471-3","article-title":"Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: Clinical, immunological, and microbiological aspects","volume":"33","author":"Becorpi","year":"2018","journal-title":"Lasers Med. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/GME.0000000000001738","article-title":"Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy","volume":"28","author":"Quick","year":"2021","journal-title":"Menopause"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e2255697","DOI":"10.1001\/jamanetworkopen.2022.55697","article-title":"Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause","volume":"6","author":"Mension","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women","volume":"384","author":"Dorling","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2022.08.013","article-title":"Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: A randomized controlled trial","volume":"167","author":"Gold","year":"2022","journal-title":"Maturitas"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr3097","article-title":"Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy","volume":"14","author":"Bundred","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/13697130903305627","article-title":"Effects of bazedoxifene\/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar\/vaginal atrophy","volume":"13","author":"Bachmann","year":"2009","journal-title":"Climacteric"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifene\/conjugated estrogens for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/GME.0000000000000624","article-title":"Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo","volume":"23","author":"Eigeliene","year":"2016","journal-title":"Menopause"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/GME.0000000000001497","article-title":"Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: A phase II, randomized, double-blind, placebo-controlled trial","volume":"27","author":"Hirschberg","year":"2020","journal-title":"Menopause"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.2017.75.8995","article-title":"Interventions to Address Sexual Problems in People with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline","volume":"36","author":"Carter","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: A double- blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3892\/ijo.2014.2778","article-title":"Estrogen receptor \u03b2 selective agonists reduce invasiveness of triple-negative breast cancer cells","volume":"46","author":"Hinsche","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"van Barele, M., Heemskerk-Gerritsen, B., Louwers, Y., Vastbinder, M., Martens, J., Hooning, M., and Jager, A. (2021). Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. Cancers, 13.","DOI":"10.3390\/cancers13112506"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/550\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:10:53Z","timestamp":1760123453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":85,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040550"],"URL":"https:\/\/doi.org\/10.3390\/ph16040550","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}